Status:
UNKNOWN
An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients
Lead Sponsor:
Xuanwu Hospital, Beijing
Conditions:
Neuromyelitis Optica
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This is an open-label study, to evaluate the efficacy and safety of a BTK inhibitor zanubrutinib in participants with NMOSDs.
Detailed Description
This is an open, single-center clinical study to evaluate the efficacy and safety of Zanubrutinib in the treatment of recurrent neuromyelitis optica spectrum disease. Patients were required to be diag...
Eligibility Criteria
Inclusion
- Patients must meet the NMOSD diagnostic criteria set by the international NMO Diagnostic Group (IPND) in 2015.
- Serum AQP4-IgG positive.
- Clinical evidence of at least 2 documented relapse (including first attack) in the last 2 years, with at least 1 relapse within 12 months prior to screening.
- Extended Disability Status Scale (EDSS) score ≤7.5 at screening.
- Age 18 to 75 years inclusive, weight at least 35 kg at the time of informed consent.
- If the patients were using the following baseline treatment for relapse prevention, they must be treated at a steady dose for at least 4 weeks prior to enrollment:
- Azathioprine, metecophenol ester and other immunosuppressive agents
- Oral corticosteroid (≦30mg/ day prednisone tablet or equivalent dose of other hormones)
- (patients or their legal representatives) can provide written informed consent indicating that they understand and agree to comply with the requirements of the study protocol.
Exclusion
- Continuous treatment with strong or moderate CYP3A inhibitors or inducers is required during the study period. Patients were excluded if they had taken a potent or moderate CYP3A inhibitor or inducer within 7 days prior to administration of the study drug (or had stopped taking these drugs for less than 5 half-lives).
- Previously treated with BTK inhibitors (e.g., ibrutinib).
- Allergic to the study drug or any of the ingredient.
- Desease relaps (including first episode) within the previous 30 days.
- Pregnancy or lactation.
- Previous or current malignancy, except locally recurrent cancers that have received radical treatment (e.g. excised basal or squamous cell skin cancer, cervical or breast cancer in situ).
- Currently central nervous system (CNS) disease that may affect the evaluation of NMOSD.
- Serious and uncontrolled conditions considered by the investigator that could affect safety, compliance and endpoint evaluation, or need for use of a drug not permitted in the protocol.
- Disease that could affected drug absorption, distribution, metabolism, and excretion determined by the investigator.
- Any major clinical infection lead to hospitalization or parenteral antibiotic treatment within 1 month prior to screening; Or other infections that may be aggravated due to the study determined by the investigator.
- Active, latent or undertreated mycobacterium tuberculosis (TB) infection
- Known primary immunodeficiency or underlying disease such as human immunodeficiency virus (HIV) infection.
- Hepatitis B or C virus infection by serological test.
- Received B-cell targeted therapy (e.g. Rituximab) within 6 months prior to the initial administration of the study drug.
- Received biologics such as tozizumab within 12 weeks prior to initial administration of the study drug.
- Received live attenuated vaccine during the screening and study periods, or any live virus vaccine within 8 weeks prior to initial administration.
- Abnormal and clinically significant in ECG examination during screening.
- Uncontrolled hypertension (SBP\>160 mmHg or DBP ≥ 95 mmHg)
- Grade 3 or 4 heart Failure, (NYHA scale).
- Severe liver insufficiency (Child-pugh C).
- Aspartate aminotransferase (AST)\>3 times the upper limit of normal (ULN) and/or alanine aminotransferase (ALT)\>3ULN and/or bilirubin \>2ULN.
- Estimated creatinine clearance \<30 mL/min or requiring dialysis.
- Inability to receive MRI scans
- A history of clinically significant CNS trauma
- Received experimental drug or other experimental treatment within 4 weeks prior to screening or during 5 pharmacokinetic half-lives or duration of biological effects, whichever is longer.
- Participate in another clinical study.
- Accept any of the following:
- BCG vaccination within 1 year prior to screening.
- Prior bone marrow transplant, hematopoietic stem cell transplant, or systemic radiation therapy.
- Received intravenous gamma globulin within 30 days prior to screening.
- Plasmapheresis or leukocyte separation within 90 days prior to screening
- Abnormal white blood cell count, neutrophil count, lymphocyte count, or platelet count during the screening and were considered unsuitable for study by investigator
- Inability to swallow capsules or medical conditions that significantly affect gastrointestinal function
- A history of severe hemorrhagic disorders such as hemophilia A, hemophilia B, von willebrand disease, or a history of spontaneous bleeding requiring blood transfusion or other medical intervention.
- History of stroke or intracranial hemorrhage within 6 months prior to screening
- Current alcohol, drug or chemical abuse, or history of such abuse within 1 year prior to screening.
- Anticoagulants or a combination of anticoagulants and antiplatelet agents is ongoing or planned.
- Any other circumstances in which the investigator or sponsor considers the patient unsuitable for study participation.
Key Trial Info
Start Date :
May 7 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05356858
Start Date
May 7 2022
End Date
October 1 2024
Last Update
May 20 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
XuanWu Hospital
Beijing, Beijing Municipality, China, 100053